China's COVID-19 Vaccine Administered To A Million People

Oxford vaccine candidate found safe in elderly, offered immunity against SARS-CoV-2 in all age groups

Oxford-AstraZeneca vaccine shows promise in elderly, trial results by Christmas

The results were consistent across ages 18 years to 85 years, races and ethnic groups, the companies said. It is also now being trialled in South Africa.

They are also testing whether the vaccine stops people developing Covid-19 in larger, phase three trials.

"We're really delighted with the results".

On the other hand, Moderna Inc said its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trial, becoming the second US company in a week to report results that far exceed expectations.

"And the first data are really encouraging".

The findings show the vaccine creates as strong an immune response in those over age 70 as it does in younger adults.

COVID-19: Mayo Clinic is Expanding its ICU Capacity in Rochester
In coming weeks, hospitalizations and deaths are expected to increase as the number of daily coronavirus cases continues to rise.


"The Phase II interim data for AZD1222 suggests older individuals have lower reactogenicity whilst still maintaining a robust immune response", said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D in a statement.

Results of those trials should definitely be known by Christmas, the Oxford Vaccine Group's director Andrew Pollard said, adding it was too early to know whether and how well the vaccine works in preventing the COVID-19 disease. The study, therefore, includes only healthy participants and not those with comorbidities.

Mittal said those working on the front lines of fighting the virus will be first the receive the vaccine.

Volunteers, aged between 18 and 59 from Beijing, Chongqing and Hunan provinces, received the vaccine to determine whether it is safe for use on humans, state-run Xinhua news agency reported.

Dr Maheshi Ramasamy, an investigator at the Oxford Vaccine Group, said: "The next step will be to see if this translates into protection from the disease itself".

Meanwhile, cases of COVID-19 and deaths from the illness continue to rise.

Luiz hits Ceballos in Arsenal training session
Luiz and Ceballos were not part of the Brazil and Spain squads and remained in London where they have continued to train. Thomas Partey will miss Arsenal's trip to Leeds United this weekend due to a thigh injury.


"My policy is that everyone who wants a vaccine should be able to receive one", Netanyahu said, alluding to recent government denials that it meant to make the vaccine mandatory.

"It was also quite clear that two doses of vaccine are better than one dose".

"I think we're getting close, and it's definitely going to be before Christmas based on the progress", Pollard said in an interview with the BBC.

"We still need to collect all the data on that though", she said.

"Up until now, we've looked at antibody, which protects the circulating fluid (blood and tissue flow) from the virus".

He said, "We have two challenges in front of us now". And it turns out that older adults are less likely to have local reactions where they got the injection and symptoms on the day of vaccination compared to younger people.

Apple Paying $113 Million to Settle U.S. iPhone Throttling Investigation
This means that Apple is affirmative that a future software update will be able to fix the problems. Under Wednesday's settlement, Apple will pay Nebraska $1,339,427.


Larger studies are now underway to evaluate immunogenicity, safety and efficacy in older adults with a wider range of comorbidities.

Latest News